Aduro BioTech Inc (NASDAQ:ADRO) insider Jennifer Lew sold 6,600 shares of Aduro BioTech stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $12.17, for a total value of $80,322.00. Following the transaction, the insider now owns 49,195 shares of the company’s stock, valued at $598,703.15. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Jennifer Lew also recently made the following trade(s):
- On Monday, July 3rd, Jennifer Lew sold 12,000 shares of Aduro BioTech stock. The stock was sold at an average price of $11.14, for a total value of $133,680.00.
- On Wednesday, June 28th, Jennifer Lew sold 12,000 shares of Aduro BioTech stock. The stock was sold at an average price of $11.19, for a total value of $134,280.00.
Aduro BioTech Inc (ADRO) traded down 1.22% during mid-day trading on Wednesday, reaching $12.15. The company had a trading volume of 354,202 shares. The stock’s market capitalization is $895.16 million. Aduro BioTech Inc has a one year low of $8.75 and a one year high of $16.18. The company’s 50-day moving average is $12.28 and its 200-day moving average is $10.96.
Aduro BioTech (NASDAQ:ADRO) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.02. The business had revenue of $5.90 million during the quarter, compared to the consensus estimate of $3.98 million. Aduro BioTech had a negative net margin of 327.87% and a negative return on equity of 31.97%. The business’s revenue was down 84.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.03 earnings per share. Equities research analysts anticipate that Aduro BioTech Inc will post ($1.37) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This story was posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/2796017/insider-selling-aduro-biotech-inc-nasdaqadro-insider-sells-6600-shares-of-stock.html.
Several institutional investors have recently added to or reduced their stakes in ADRO. State Street Corp raised its position in Aduro BioTech by 1.3% in the fourth quarter. State Street Corp now owns 573,804 shares of the biotechnology company’s stock valued at $6,544,000 after buying an additional 7,597 shares in the last quarter. Fox Run Management L.L.C. purchased a new position in shares of Aduro BioTech during the first quarter valued at $202,000. Piermont Capital Management Inc. purchased a new position in shares of Aduro BioTech during the first quarter valued at $386,000. Norges Bank purchased a new position in shares of Aduro BioTech during the fourth quarter valued at $3,266,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Aduro BioTech during the fourth quarter valued at $241,000. 35.60% of the stock is owned by institutional investors.
Several research analysts have recently commented on ADRO shares. Zacks Investment Research upgraded Aduro BioTech from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Tuesday, July 4th. Rodman & Renshaw started coverage on Aduro BioTech in a research note on Monday, May 1st. They set a “buy” rating and a $18.00 target price for the company. HC Wainwright started coverage on Aduro BioTech in a research note on Monday, May 1st. They set a “buy” rating and a $18.00 target price for the company. Canaccord Genuity reiterated a “buy” rating and set a $30.00 target price on shares of Aduro BioTech in a research note on Wednesday, May 3rd. Finally, BidaskClub upgraded Aduro BioTech from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $19.00.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech Inc and related companies with MarketBeat.com's FREE daily email newsletter.